ENDOTHELIAL MODULATION OF LUNG VASCULAR PERMEABILITY
Project Number5R01HL048816-02
Contact PI/Project LeaderSCHAEFFER, RICHARD C
Awardee OrganizationUNIVERSITY OF ARIZONA
Description
Abstract Text
A persistent increase in lung endothelial permeability to protein is a
hallmark of the Adult Respiratory Distress Syndrome. Moreover,
inflammatory mediator-initiated increase in the Area/Unit pathlength
(Arho/Ax) of the Endothelial Junctional Space is the foundation of
elevated solute permeability of the microvascular wall. The long term
objectives of this research are to better understand the endothelial
mechanisms that modulate pulmonary microvascular permeability to
macromolecules. Intracellular level of cyclic nucleotide, adenosine
3',5' cyclic monophosphate (cAMP), or the activities of protein kinase
C and A, and intracellular free Ca2+ concentration ([Ca2+]) will be
specifically manipulated in vitro. The hypotheses to be tested are: 1)
Agonist-induced changes of intracellular second messengers modulate
endothelial morphology leading to the discrete Solute Permeability
Mechanism: Restricted Diffusion or Convection and 2) Different mediator
induced distinct cellular responses by discrete spatiotemporal
alterations in [Ca2+] of cytoskeleton protein will be assessed in
specific aims 1-3. Specific aim 4 will test the Crone Hypothesis. These
aims will be tested using bovine lung endothelial cells from two distinct
locations: large vessel (pulmonary artery endothelial cells, AEC) and
macrovessel (MEC). Monolayers of AEC and MEC will be used as cellular
models of the lung microvascular barrier to solutes. The following
assays will be used: 1) The solute permeability mechanisms that define
the barrier properties of endothelial monolayer will be measured for each
experimental condition, 2) Endothelial surface area will be measured from
differential interference contrast (DIC) digital images using Image-1
software (universal Imaging Corp), 3) Agonist-induced spatiotemporal
alterations of intracellular [Ca2+] will be measured by fura-2
fluorescence digital images. 4) Agent-induced rearrangement of
endothelial F-actin/myosin II will be measure by fluorescence digital
images in living cells, 5) Electron microscopic analysis by rotary
shadowing of the endothelial cytoskeleton will be performed, 6)
Intracellular [cAMP] and [cGMP] will be measured by radioimmunoassay, 7)
Protein kinase activities will be measured by P-labelled immunoaffinity
protein SDS polyacrylamide gel electrophoresis.
No Sub Projects information available for 5R01HL048816-02
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01HL048816-02
Patents
No Patents information available for 5R01HL048816-02
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01HL048816-02
Clinical Studies
No Clinical Studies information available for 5R01HL048816-02
News and More
Related News Releases
No news release information available for 5R01HL048816-02
History
No Historical information available for 5R01HL048816-02
Similar Projects
No Similar Projects information available for 5R01HL048816-02